Chonnam Med J.
2023 Jan;59(1):24-30. 10.4068/cmj.2023.59.1.24.
Immune Response to COVID-19 Vaccination in Hematologic Malignancies: A Mini-Review
- Affiliations
-
- 1School of Paramedicine, Guilan University of Medical Sciences, Rasht, Iran
- 2Department of Clinical Biochemistry, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
- KMID: 2538693
- DOI: http://doi.org/10.4068/cmj.2023.59.1.24
Abstract
- The outbreak of the COVID-19 infection has led to the rapidity of vaccine usage in recent years. Emerging data indicate that the efficacy of vaccination against COVID-19 was about 95% in the general population, though its impact is impaired in patients with hematologic malignancies. As such, we decided to research the publications in which the authors reported the impacts of COVID-19 vaccination in patients suffering from hematologic malignancies. We concluded that patients with hematologic malignancies have lower responses, antibody titers as well as an impaired humoral response following vaccination, notably in patients with chronic lymphocytic leukemia (CLL) and lymphoma. Furthermore, it seems that the status of treatment can significantly affect the responses to the COVID-19 vaccination.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Diabetes and COVID-19 Vaccination
- A Case of Papulopustular Rosacea-Like Eruptions Following COVID-19 Vaccination
- Treatment for Immune Thrombocytopenia in Coronavirus Disease 2019 (COVID-19) Infection after COVID-19 Vaccination: A Case Report
- Evaluation of Immune Response after Vaccinations Post-chemotherapy in Childhood Cancer Survivors
- Vestibular Neuritis after COVID-19 Vaccination
